AI disease modelling startup CytoReason to scale up in US The company aims to reach more biotech and pharma companies, increase the speed and accuracy of drug development and benefit patients.

https://www.israel21c.org/ai-disease-modelling-startup-cytoreason-to-scale-up-in-us/ Israeli startup CytoReason, which develops computational disease models for predictive insights, has secured $80 million in funding that will scale up its AI disease models and enable it to establish a hub in the United States.